ALGS · Aligos Therapeutics, Inc.
$6.93
-0.14 (-1.98%)
At close · Aug 28
Going-concern doubt
— cleared Aug 6, 2026
The latest filing no longer states the doubt (first flagged May 7, 2026).
View the 10-Q filed Aug 6, 2026Market Cap
$26.95M
Shares
3.59M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$7.07
Open$7.44
Day$6.82–7.50
52W close$4.08–13.30
Avg vol 30d129K
Short int568K · 15.8% float · 2.7d
Short vol32%
DataAug 2024–Aug 2026
Filing10-Q · Aug 6
Raw chart and full-history price indicators begin at the captured split on Aug 19, 2024; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Buy
Momentum
Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.5 · calm
Equity put/call 0.39
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−1%
below
Price vs 50-day avg
+21%
above
RSI (14)
59
neutral
MACD trend
Positive
52-week position
32%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+64%
trailing
6-month return
+1%
trailing
YTD return
−24%
this year
Relative strength
−13%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $6 › 200d $7 — 200d above 50d
Institutional flow
Distributing
-11% holders QoQ · +5 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
15.83% of float · ▼ -6.3% MoM · 2.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
31 holders — mid 3-yr range
Squeeze score
65
elevated · 0–100
Fundamentals
Revenue growth
−39%
Y/Y
EPS growth
+88%
Y/Y
Free cash flow
$-82.6M
Balance sheet
$18.3M
net cash
Quant / Vol
risk profile
Volatility
90%
annualized · 1-yr
Max drawdown
−69%
past year
ATR
8.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−1%
Neutral
Price vs 50-day avg
+21%
Bullish
RSI (14)
59
Neutral
MACD trend
Positive
Bullish
52-week position
32%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $6 › 200d $7 — 200d above 50d
Institutional flow
Distributing
-11% holders QoQ · +5 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
15.83% of float · ▼ -6.3% MoM · 2.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
31 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $4
Now $7 · 32%
Range high $13
vs 200-day avg -1%
vs 50-day avg +21%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ALGS
this stock
Aligos Therapeutics, Inc.
|
$26.95M | -24.1% | -39.5% | — | 15.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +20.8% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.27B | +4.6% | +20.8% | 19.6 | 2.3% |
|
ARGX
Argenx SE
|
$65.12B | +25.9% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.92B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Aug 19, 2024; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ALGS | +9.8% | +63.7% | +1.3% | +67.1% | -24.1% |
| SPY | +1.1% | +4.0% | +14.7% | +3.2% | +13.1% |
| vs SPY | +8.7% | +59.7% | -13.4% | +63.9% | -37.2% |
Key facts
CIK
1799448
CUSIP
01626L204
13F (30d)
28 filings
28 filers
Visit website
Investor relations